Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape

Abstract

Abstract This report describes the successful transition of two familial patients with HAE from injectable to oral prophylaxis without tapering prior therapy or employing a complex transition protocol.

Keywords

• berotralstat
• Haegarda
• hereditary angioedema
• shared decision‐making
• switching
• treatment burden